Assessment of Haematological Parameters in Patients under Carbamazepine Antiepileptic Drug Treatment

Nesreen Hassan Ali, Amira Ahmed K. Humeida

Abstract


AIM Carbamazepine is iminostilbene derivative used as an antiepileptic drug against partial and tonic-clonic seizures and is also used in trigeminal neurologic and bipolar affective disorders. According to previous studies, carbamazepine is associated  with a wide range of haematological toxicities including leucopenia, reduced haemoglobin and red blood cell count,  and thrombocytopenia.

This study was conducted to establish the effect of carbamazepine as an antiepileptic drug in haematological parameters in patients using it for different durations.

METHOD In this study, 50 individuals were recruited as the study group and 50 individuals as the control group. Seventeen patients were female while 33 were male in the study group. Twenty-two were female and  28 were male in the control group. In both groups age-range was  15-70 years. We included patients under treatment for at least one month. Subjects with neurological deficits, haematological deficits, or history of drugs/alcohol abuse at recruitment were excluded from the study. Route of administration was oral. Blood samples (2.5 ml each sample) were collected from all patients and controls in Ethyelene diamine tetra acetic acid (EDTA) blood tubes, Full Blood Counts (FBCs) were carried out using automated Huma count 30 cell counter.

RESULTS  In this study administration of carbamazepine at different doses, different duration and with different severity of disease produced slight differences in mean haemoglobin, haematocrit and white blood cell count with p value > 0.05. The mean platelet counts were also within normal range in all patients. Addition of folic acid to carbamazepine therapy did not produce any clinically significant changes in haematological parameters. Our study did not reveal any significant relationship between severity of disease, duration or dose of carbamazepine and changes on FBC results.

CONCLUSION Carbamazepine had no significant difference in FBC parameters among epileptic patients who used it as treatment.


Keywords


Blood Cell Count; Carbamazepine; Antiepileptic Drug; Epilepsy; Anaemia; Leukopenia; Thrombocytopenia

Full Text:

HTML PDF

References


Sridharan R. Epidemiology of epilepsy. Current Science. 2002;82(6):664-670.

Pond D, Bidwell B and Stein L. A survey of 14 general practices. Psychiatr Neurologia, Neurochirurgia. 1960;63:217–236.

Lippert M, Anderson VE, Quattlebaum T et al. Benign familial neonatal convulsions linked to genetic marker on chromosome 20. Nature. 1989;337 (6208):647-648.

Lewis TB, Leach RJ, Ward K et al. Genetic heterogeneity in benign familial neonatal convulsions: Identification of new locus on chromosome 8q. Amjhum Genet. 1993;53(3):670-675.

Beran RG, Hall L, Michelazzi J. An accurate assessment of prevalence ratio of epilepsy adequately adjusted by influencing factors, Neuroepidemiology. 1985;4 (2):71-81.

Bora I, Demir AB. The new antiepileptic drug or the traditional antiepileptic drugs. Update in terms of drug side effects . J Neurol Res 2012;2(6):255-260.

McNamara JO. Pharmacotherapy of epilepsies. In: Brunton LL, Lazo JS, Parker KL, editors. The pharmacological basis of therapeutics. 11th ed. New Delhi: McGraw Hill; 2006. P511.

Physicians Desk Reference 61sted, Thomson PDR, Montvale, NJ2007; P3171.

Lide DR. CRC Handbook of chemistry and physics 86TH Edition 2005-2006. CRC press, Taylor and Francis, Boca Raton, FL 2005, p 3-140.

O’Neil MJ, (Ed).The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals. 13thEdition, Whitehouse station, NJ: Merck and Co, Inc. 2001, p298.

Granger P et al. Modulation of the gamma-aminobutyric acid type a receptor by the antiepileptic drugs carbamazepine and phenytoin. Molpharmacol .1995;47:1189-1196.

Hooper WD, Du betz DK, Bocher F et al. Plasma protein binding of carbamazepine. ClinPharmacol Ther.1975;17:433-40.

Kutt H. Carbamazepine. Chemistry and methods of determination complex partial seizures and their treatment. In: Penry JK, Daly DD, eds. Advances in Neurology. New York, NY: Raven press, 1975;11:249-61.

Porter RJ. How to initiate and maintain carbamazepine therapy in children and adults. Epilepsia. 1987;28:s59-63.

Tohen M, Castillo PHJ, Baldessarini RJ, Zarate C Jr, Kando JC. Blood dyscrasias with carbamazepine and valproate: apharmacoepidemiological study of 2228 patients at risk. Am Jpsychiat.1995;152-413-8.

Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neural. 1982;11:309-12.

Schweiger FJ, Kelton JG, Meissner H, Klein M, Berger S, Mallory WJ, Falk J, Keating A. Anticonvulsant-induced marrow suppression and immune thrombocytopenia. ActaHaematol.1988;80:54-8.

Li ZH, Li P, Randal T. Effect of a human pharmaceutical carbamazepine on antioxidant responses in brain of a model teleost in vitro: an efficient approach to biomonitoring. J Appl Toxicol. 2010; 30 (7):644-8.

McCord JM. Superoxide radical: Contradiction and paradoxes. Proc Soc Exp Bio Med. 1989;209:112-7.

Dal –Pizzol F, Klimt F, Vienna MM, Schroder N, Quevedo J, Benfato MS, Moreira JC, Walz R. Lipid peroxidation in hipppocampus early and late after status epilepticus induced by Pilocarpine of Kainic acid in Wistar rats . Neurosci Lett. 2000;291(3):179-82.

Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B, Yologlu S . Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain dev. 2003;25:113-15.

Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 2000;41:107-39.

Isojarvi JI, Pakarinen AJ, Myllyla VV. Basic hematological parameters, serum gamma -glutamyl-transferase activity, and erythrocyte dilate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy. Seizure.1997;6:207-211.

Ishikita T, Ishiguro A, Fujisawa K, Tsukimoto I, Shimbo T. Carbamazepine-induced thrombocytopenia defined by a challenge test. Am J Hematol. 1999;62:52–55.

Kumar S. Anticonvulsivant-hypersensitivity syndrome in a child. Neurol India. 2003;51:427

Kornberg A, Kobrin I. IgG antiplatelet antibodies due to carbamazepine. Acta Haematol. 1982;68:68–70.

Tutor-Crespo MJ, Hermida J, Tutor JC. Relation of blood platelet count and carbamazepine and oxcarbazepine treatment with Daily Dose, and serum concentration of carbamazepine, carb-10, 11-Epoxide, and 10-hydroxycarbamazepine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1):91–94.

Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B,Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain dev. 2003;25:113-15.

Horwitz SL, Klipstein FA, Lovelace RE. Relation of abnormal folate metabolism to neuropathy developing during anticonvulsive drug therapy. Lancet. 1968;1:536.